Swiss Drugmaker Novartis to Invest $23 Billion to Expand US Manufacturing, Operations
The company plans to build or expand 10 facilities and bring 100 percent of its key medicines’ production inside the United States over five years.
By Chase Smith
4/10/2025 Updated: 4/10/2025
Swiss pharmaceutical company Novartis announced on April 10 that it will invest $23 billion over the next five years to expand its U.S. manufacturing and research operations.
The initiative includes the construction or expansion of 10 facilities nationwide, with a focus on building out domestic production capacity for the company’s most important medicines. Novartis said the investment will allow it to manufacture 100 percent of its key drugs end-to-end in the United States—a significant increase from current levels.
“As a Swiss-based company with a significant presence in the U.S., these investments will enable us to fully bring our supply chain and key technology platforms into the U.S. to support our strong U.S. growth outlook,” Novartis CEO Vas Narasimhan said in a statement. “These investments also reflect the pro-innovation policy and regulatory environment in the U.S. that supports our ability to find the next medical breakthroughs for patients.”
The planned expansion includes four new manufacturing sites in states to be determined, two facilities for cancer-treatment radioligand therapy (RLT) in Florida and Texas, and a new biomedical research hub in San Diego, California. Three existing RLT plants—in California, Indiana, and New Jersey—will also be expanded. The company expects to create nearly 1,000 direct jobs and around 4,000 additional U.S. jobs through the buildout.
The new San Diego research complex, which is expected to open between 2028 and 2029, will serve as the company’s second U.S. research and development hub alongside its Cambridge, Massachusetts, site.
Novartis said the investment supports its broader growth strategy through 2029 and reflects confidence in the U.S. market and regulatory environment.
...
READ MORE: https://www.theepochtimes.com/business/swiss-drugmaker-novartis-to-invest-23-billion-to-expand-us-manufacturing-operations-5839892?ea_src=frontpage&ea_cnt=a&ea_med=top-news-3-top-stories-0-title-0
***
Chân thành cám ơn Quý Anh Chị ghé thăm "conbenho Nguyễn Hoài Trang Blog"
Xin được lắng nghe ý kiến chia sẻ của Quý Anh Chị trực tiếp tại Diễn Đàn Paltalk: 1Latdo Tapdoan Vietgian CSVN Phanquoc Bannuoc.
Kính Chúc Sức Khỏe Quý Anh Chị.
conbenho
Tiểu Muội quantu
Nguyễn Hoài Trang
11042025
__________________________
Cộng sản Việt Nam là TỘI ÁC
Bao che, dung dưỡng TỘI ÁC là ĐỒNG LÕA với TỘI ÁC
No comments:
Post a Comment